Roivant Sciences (NASDAQ:ROIV – Get Rating) had its target price upped by equities researchers at HC Wainwright from $14.00 to $15.00 in a report released on Wednesday, The Fly reports. HC Wainwright’s price target points to a potential upside of 65.02% from the company’s previous close.
Other analysts have also issued research reports about the company. JPMorgan Chase & Co. increased their price objective on Roivant Sciences from $10.00 to $11.00 and gave the company an “overweight” rating in a research note on Monday, February 13th. The Goldman Sachs Group raised their price objective on Roivant Sciences from $10.00 to $11.00 and gave the company a “buy” rating in a research report on Thursday, January 19th. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $12.80.
Roivant Sciences Stock Up 0.6 %
ROIV stock opened at $9.09 on Wednesday. Roivant Sciences has a 1-year low of $2.87 and a 1-year high of $10.00. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 0.26. The company’s 50 day moving average is $8.16 and its 200 day moving average is $7.61. The stock has a market cap of $6.89 billion, a price-to-earnings ratio of -5.11 and a beta of 1.22.
In related news, major shareholder Svf Investments (Uk) Ltd sold 12,000,000 shares of the business’s stock in a transaction that occurred on Monday, March 20th. The stock was sold at an average price of $8.00, for a total value of $96,000,000.00. Following the transaction, the insider now directly owns 83,031,667 shares of the company’s stock, valued at approximately $664,253,336. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. In other Roivant Sciences news, Director Vivek Ramaswamy sold 4,000,000 shares of the company’s stock in a transaction on Wednesday, February 22nd. The stock was sold at an average price of $7.95, for a total value of $31,800,000.00. Following the completion of the sale, the director now directly owns 54,409,211 shares in the company, valued at approximately $432,553,227.45. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, major shareholder Svf Investments (Uk) Ltd sold 12,000,000 shares of the company’s stock in a transaction on Monday, March 20th. The stock was sold at an average price of $8.00, for a total value of $96,000,000.00. Following the sale, the insider now owns 83,031,667 shares of the company’s stock, valued at $664,253,336. The disclosure for this sale can be found here. Insiders have sold a total of 16,509,880 shares of company stock valued at $132,131,966 in the last ninety days. Corporate insiders own 13.00% of the company’s stock.
Institutional Investors Weigh In On Roivant Sciences
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ROIV. Wellington Management Group LLP purchased a new stake in Roivant Sciences in the first quarter valued at about $88,773,000. Patient Square Capital LP acquired a new stake in Roivant Sciences during the fourth quarter worth about $54,539,000. State Street Corp boosted its position in Roivant Sciences by 129.1% during the first quarter. State Street Corp now owns 8,032,952 shares of the company’s stock worth $59,283,000 after purchasing an additional 4,525,910 shares in the last quarter. Baker BROS. Advisors LP lifted its position in shares of Roivant Sciences by 566.6% in the first quarter. Baker BROS. Advisors LP now owns 4,777,430 shares of the company’s stock valued at $35,257,000 after acquiring an additional 4,060,777 shares in the last quarter. Finally, Rubric Capital Management LP lifted its position in shares of Roivant Sciences by 86.7% in the first quarter. Rubric Capital Management LP now owns 5,600,000 shares of the company’s stock valued at $41,328,000 after acquiring an additional 2,600,000 shares in the last quarter. 52.66% of the stock is currently owned by hedge funds and other institutional investors.
About Roivant Sciences
Roivant Sciences Ltd., a biopharmaceutical and healthcare technology company that researches and develops medicines. The company develops product candidates for the treatment of various therapeutics, including solid tumors, sickle cell diseases, hypophosphatasia, oncologic malignancies, psoriasis, atopic dermatitis, vitiligo, hyperhidrosis, acne, myasthenia gravis, warm autoimmune hemolytic anemia, thyroid eye diseases, sarcoidosis, and staph aureus bacteremia.
- Get a free copy of the StockNews.com research report on Roivant Sciences (ROIV)
- It’s Time To Take Another Bite Of Take-Two Interactive
- Zoetis Declares New Dividend, Hinting At Undervaluation
- Good News For Walmart Isn’t So Great For Everybody Else
- Eagle Materials, Answering America’s Building Supply Needs
- Pharma Giants Novartis, Lilly, Merck, and Novo Outperform Market
Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.